Cleared Traditional

K081713 - VERTEBRAL ACCESS SYSTEM BY VIDACARE (FDA 510(k) Clearance)

Class I General & Plastic Surgery device.

K081713 · Vidacare Corporation · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2008
Decision
157d
Days
Class 1
Risk

K081713 is an FDA 510(k) clearance for the VERTEBRAL ACCESS SYSTEM BY VIDACARE. Classified as Battery, Replacement, Rechargeable (product code MOQ), Class I - General Controls.

Submitted by Vidacare Corporation (Irvine, US). The FDA issued a Cleared decision on November 21, 2008 after a review of 157 days - an extended review cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4820 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General & Plastic Surgery review framework, consistent with the majority of Class II 510(k) submissions.

View all Vidacare Corporation devices

Submission Details

510(k) Number K081713 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 17, 2008
Decision Date November 21, 2008
Days to Decision 157 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
43d slower than avg
Panel avg: 114d · This submission: 157d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code MOQ Battery, Replacement, Rechargeable
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4820
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.